0001144204-19-040674.txt : 20190819 0001144204-19-040674.hdr.sgml : 20190819 20190819172718 ACCESSION NUMBER: 0001144204-19-040674 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20190819 DATE AS OF CHANGE: 20190819 EFFECTIVENESS DATE: 20190819 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TITAN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000910267 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943171940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-346935 FILM NUMBER: 191037340 BUSINESS ADDRESS: STREET 1: 400 OYSTER POINT BLVD STREET 2: SUITE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 6502444990 MAIL ADDRESS: STREET 1: 400 OYSTER POINT BLVD STREET 2: SUITE 505 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 D 1 primary_doc.xml X0708 D LIVE 0000910267 TITAN PHARMACEUTICALS INC 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA CALIFORNIA 94080 6502444990 DELAWARE None None Corporation true Marc Rubin 400 Oyster Point Blvd., Suite 505 South San Francisco CA CALIFORNIA 94080 Executive Officer Director Sunil Bhonsle 400 Oyster Point Blvd., Suite 505 South San Francisco CA CALIFORNIA 94080 Executive Officer Director Katherine Beebe 400 Oyster Point Blvd., Suite 505 South San Francisco CA CALIFORNIA 94080 Executive Officer Dane Hallberg 400 Oyster Point Blvd., Suite 505 South San Francisco CA CALIFORNIA 94080 Executive Officer Joseph A. Akers 400 Oyster Point Blvd., Suite 505 South San Francisco CA CALIFORNIA 94080 Director Rajinder A. Kumar 400 Oyster Point Blvd., Suite 505 South San Francisco CA CALIFORNIA 94080 Director M. David McFarlane 400 Oyster Point Blvd., Suite 505 South San Francisco CA CALIFORNIA 94080 Director James R. McNab, Jr. 400 Oyster Point Blvd., Suite 505 South San Francisco CA CALIFORNIA 94080 Director Scott A. Smith 400 Oyster Point Blvd., Suite 505 South San Francisco CA CALIFORNIA 94080 Director Pharmaceuticals Decline to Disclose 06b false 2019-08-09 false true true false 0 2125512 2125512 0 Represents private placement warrants to purchase up to 2,852,314 shares of common stock issued in connection with a concurrent registered direct offering. Total Offering Amount includes the securities sold in such concurrent registered direct offering. false 1 0 148786 Represents a 7% fee paid pursuant to a placement agency agreement. 0 false TITAN PHARMACEUTICALS INC /s/ Sunil Bhonsle Sunil Bhonsle CEO and President 2019-08-19